Great West Life Assurance Co. reportedly purchased Axon Enterprise, Inc. (NASDAQ: AXON) during the third quarter, as stated in the company’s most recent filing with the Securities and Exchange Commission (SEC). The institutional investor spent approximately $5,521,000 to purchase 47,715 shares in the biotechnology company. This brings the total amount of money spent to approximately $5,521,000. Great West Life Assurance Co. had a holding in Axon Enterprise totaling 0.07% of the company’s shares when the most recent reporting period closed.
Several other significant investors have been buying and selling company shares for the past few months. During the second quarter of 2018, The Trust Company of Vermont made a total investment of $28,000 in shares of Axon Enterprise. SJS Investment Consulting Inc. acquired a further investment in Axon Enterprise in the third quarter for a price close to thirty thousand dollars. During the second quarter, Sandy Spring Bank achieved an increase of 230.0% in the percentage of ownership in Axon Enterprise. The most recent quarter saw Sandy Spring Bank acquire an additional 230 shares, bringing the total number of shares it owns in the biotechnology company to a value of $31,000 to 330. This represents an increase of $31,000 from the previous quarter. During the second quarter, Crewe Advisors LLC invested approximately $37,000 into Axon Enterprise to acquire a larger share of the company’s ownership. And finally, during the first quarter of this year, Covestor Ltd. increased the amount of Axon Enterprise stock owned by 1,125.7%. Covestor Ltd purchased 394 additional shares of the biotechnology company’s stock in the most recent quarter. This brought the total number of shares directly owned by the company to 429, with a value of $59,000. To the tune of 75.62 percent, the company’s stock is owned by institutional investors and hedge funds.
AXON has been the subject of a great number of reports that were prepared by a variety of research companies. Robert W. Baird raised their price objective on Axon Enterprise shares on Thursday, December 15, in a research note that was made public. The new price objective is $200.00, increasing from $170.00. StockNews.com started providing coverage on shares of Axon Enterprise in a report on the company’s stock that was published on October 12. They advised their clients to “hold” the stock moving forward. In a research note published on Tuesday, December 13, Morgan Stanley raised their target price on shares of Axon Enterprise from $130.00 to $155.00.
Additionally, they upgraded the stock’s rating from “equal weight” to “overweight.” Credit Suisse Group’s investment bank upgraded Axon Enterprise from an “underperform” rating to a “buy” rating. It raised its price objective for the company’s stock in a research note disseminated on Tuesday, January 10. In a research report published on Wednesday, November 9, Needham & Company LLC recommended that investors “buy” shares of Axon Enterprise and increase their price target for the company’s stock from $130.00 to $200.00. Six analysts have assigned a “buy” rating to the stock, while only two have assigned a “hold” rating to the stock. According to the data provided by Bloomberg, the current consensus rating for Axon Enterprise is “Moderate Buy,” and the current consensus price objective for the company is $181.13. Additionally, the current consensus price target for the company is $181.13.
The price of AXON when trading started on Friday was $185.02. The company’s price-to-earnings ratio is 127.60, and its beta value comes in at 0.79. The company currently has a market capitalization of 13.17 billion dollars. The stock has traded at an average moving price of $177.44 over the past 50 trading days, while its moving average price over the past 200 trading days has been $145.33. Axon Enterprise, Inc. hit a low point over the past year of operations of $82.49, while the company reached a high point throughout $193.85. The debt-to-equity ratio is 0.01, the quick ratio is 2.39, and the current ratio is 2.79. The debt-to-equity ratio is an indicator of financial health.
On November 8, 2018, Axon Enterprise (NASDAQ: AXON) released the most recent quarterly results report that it has made available. The biotechnology company reported earnings per share for the quarter of $0.30, which was $0.24 more than the analysts had predicted on average. The following are the financial results for Axon Enterprise: a net margin of 9.75% and a return on equity of 9.88%. The revenue for the quarter came in significantly higher than the $276.99 million analysts had anticipated, coming in at $311.75 million instead. Axon Enterprise, Inc. is expected to generate earnings of $0.54 per share in the current fiscal year, according to projections made by industry experts.
On January 17, relevant information also included the fact that Chief Executive Officer Patrick W. Smith sold 71,499 shares of the company’s stock. A total of 13,282,369.23 dollars’ worth of the company’s shares were traded in the market, with each share averaging 185.77 dollars. After the transaction is finalized, the chief executive officer will become the owner of 2,254,734 shares. The current market price for these shares is $418,861,935.18. Follow the link, which will take you to a filing submitted to the Securities and Exchange Commission. You will have the opportunity to acquire additional information regarding the transaction. In related Axon Enterprise news, Chief Operating Officer Joshua Isner sold 5,537 shares of the company’s stock on Tuesday, January 17. Other Axon Enterprise-related news includes this development. When all the shares were sold, they brought in a total of $1,025,009.44, which works out to an average price of $185.12 per share. Following the conclusion of the transaction, the chief operating officer is now the owner of 235,764 shares of company stock, which have an approximate value of $43,644,631.68 at present. You might find a filing that explains the transaction in greater detail on the Securities and Exchange Commission (SEC) website.
Additionally, on January 17, Patrick W. Smith, Chief Executive Officer of Axon Enterprise, sold 71,499 shares. It was determined that each share was sold for an average price of $185.77, which resulted in the total value of the stock transaction being $13,282,369.23. Following the conclusion of the transaction, the Chief Executive Officer now directly owns a total of 2,254,734 shares of the company’s stock, which have an approximate value of $418,861,935.18. Disclosures that are related to the sale might be found in this section of the website. As a result of recent transactions involving company insiders, a total of 101,429 shares with a value of $18,596,402 were sold. Corporate insiders currently own ninety percent of the equity in the company they work for.
Axon Enterprise, Inc. is in the business of creating conducted electrical weaponry for personal protection and manufacturing and selling said weaponry to customers. TASER and software and sensors are the two operating segments that form this company’s overall product offering. In addition to their electric weaponry and the equipment that goes along with it, the TASER company offers various other services.
